EcoDrugPlus

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSIPUG00000009072
Gene Symbol: NTRK2
3 Cross references
209 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSIPUG00000006577
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSIPUG00000017658
Gene Symbol: NTRK2B
3 Cross references
210 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3a

Ensembl ID : ENSIPUG00000008905
Gene Symbol: NTRK3A
3 Cross references
202 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3b

Ensembl ID : ENSIPUG00000022403
Gene Symbol: NTRK3B
3 Cross references
193 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSIPUG00000019775
Gene Symbol: NFE2L2A
3 Cross references
216 Possible Orthologues:

Nicastrin

Ensembl ID : ENSIPUG00000018843
Gene Symbol: NCSTN
3 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase 1

Ensembl ID : ENSIPUG00000015223
Gene Symbol: NAMPT1
3 Cross references
225 Possible Orthologues:

Nischarin

Ensembl ID : ENSIPUG00000010896
Gene Symbol: NISCH
3 Cross references
209 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSIPUG00000015006
Gene Symbol: NOS2
2 Cross references
164 Possible Orthologues:

Nitric Oxide Synthase 2b, Inducible

Ensembl ID : ENSIPUG00000015080
Gene Symbol: NOS2B
3 Cross references
164 Possible Orthologues:

Notch Receptor 1a

Ensembl ID : ENSIPUG00000005717
Gene Symbol: NOTCH1A
4 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).